In PDAC, LRRC15+CAFs form tumor-peripheral barriers absent in normal tissue, correlate with anti-PD-L1 resistance in 600+ patients, and represent a TGFβ-dependent therapeutic target (Dominguez et al., 2020). This evidence concerns the gene CD274 and neoplasm.